Professor Hardiman trained in Neurology in Boston prior to her appointment as a Consultant Neurologist at Beaumont Hospital Dublin. In 2011, she established the Academic Unit of Neurology at Trinity College Dublin and was appointed the first Professor of Neurology in the country in 2013. In 2015 she was elected as a Fellow of Trinity College Dublin, and was of the first three active clinicians ever to be elected as a Member of the Royal Irish Academy in 2015. She is the recipient of many international honours and awards, and a recognized world leader in ALS and FTD research. Her research interests are in clinical and translational neuroscience and she is world leader in the epidemiology, phenotype, genomics and neural networking of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, and related conditions. She has published over 350 peer reviewed publications, and her work is funded by the Health Research Board, Science Foundation Ireland, and the charities ALSA and MNDA, IMNDA and RMN.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.